A 67-year-old woman who stopped using large daily amounts of high-potency cannabis concentrate developed paranoid delusions approximately four weeks later. Her symptoms resolved with short-term antipsychotic treatment and did not return. This single case report raises legitimate clinical questions about cannabis withdrawal and psychosis risk in older adults, but it cannot establish causation or be generalized beyond one patient’s experience.

Older adults represent one of the fastest-growing populations of cannabis users, yet geriatric-specific evidence on psychiatric risks during both active use and cessation remains nearly nonexistent. As high-potency concentrate products become more accessible and long-term use among aging adults accumulates, clinicians have almost no controlled data to guide cessation management. This case report surfaces a clinical scenario that practitioners are likely to encounter with increasing frequency: a psychiatrically vulnerable older patient who develops new and severe symptoms not during cannabis use, but after stopping it. Whether or not this reflects a distinct withdrawal syndrome, the gap in clinical guidance is real and consequential.

Cannabis withdrawal has traditionally been characterized by irritability, insomnia, anxiety, and appetite changes, symptoms that are uncomfortable but generally self-limited. However, a small and growing body of case literature has described a more severe outcome: new-onset psychosis emerging after heavy cannabis cessation, particularly in individuals with pre-existing psychiatric conditions. This case report from the University of New Mexico documents a 67-year-old woman with major depressive disorder, generalized anxiety disorder, and PTSD who abruptly stopped using approximately 3 grams per day of cannabis concentrate (wax containing 52 to 95% THC) after six years of daily use. She experienced typical acute withdrawal symptoms (irritability, sleep disruption, anxiety) during the first two weeks, followed by the emergence of paranoid delusions and suicidal ideation approximately four weeks after cessation.

The patient required two psychiatric hospitalizations. After her first discharge, she became nonadherent to her antipsychotic medication and relapsed within two days, underscoring the initial treatment responsiveness of the psychotic symptoms. Risperidone titrated to 2 mg per day, alongside escitalopram 20 mg daily, produced marked clinical improvement. Notably, the antipsychotic was successfully tapered and discontinued at four months, with no psychotic recurrence through six months of follow-up. A thorough medical workup including metabolic panels, thyroid function, B12, thiamine, inflammatory markers, and brain MRI excluded identifiable organic causes, though MRI did reveal chronic microvascular ischemic white matter disease. The authors acknowledge their findings are hypothesis-generating and call for prospective controlled studies to determine whether cannabis withdrawal-associated psychosis represents a distinct clinical entity.

When Stopping Cannabis May Start a Crisis: A Geriatric Case Report and What It Can, and Cannot, Tell Us

Most clinicians worry about what cannabis does to the brain while someone is using it. This case asks a different question: what happens to the brain of a vulnerable older adult when decades of heavy, high-potency use suddenly stops? The answer documented here is sobering, if preliminary. A 67-year-old woman with longstanding depression, anxiety, and PTSD developed florid paranoid delusions and suicidal ideation roughly a month after quitting her daily cannabis concentrate habit. The authors did what responsible clinicians should do: they ran a thorough medical workup, excluded identifiable organic causes, documented the timeline meticulously, followed the patient for months, and refrained from claiming more than the evidence supports. What this paper genuinely contributes is a careful clinical narrative that is internally coherent, adds a geriatric case to a small but growing literature anchored by the Chesney et al. (2024) systematic review, and demonstrates that short-term antipsychotic treatment can resolve these symptoms. That contribution is real. But the distance between a coherent clinical narrative and a proven causal relationship is vast. Seeing one person develop psychosis after stopping cannabis and concluding that cannabis withdrawal causes psychosis is like seeing someone develop a cold the day after eating sushi and concluding sushi causes colds. The timing is real, but so are dozens of other exposures and vulnerabilities that week.

The central methodological challenge here is the density of confounding. This patient had pre-existing MDD, GAD, and PTSD. She was experiencing financial distress and family conflict at the time of cessation. Collateral history described lifelong “highs and lows” that were never formally evaluated for bipolar spectrum disorder. She developed COVID-19 pneumonia during her second hospitalization, a condition with its own neuropsychiatric consequences. And her brain MRI showed chronic small vessel disease, a substrate that has been independently associated with late-onset psychosis. Any one of these factors could plausibly explain her decompensation without invoking cannabis withdrawal at all. The framing of this case as “consistent with cannabis withdrawal-associated psychosis” subtly elevates a temporal association to a diagnostic category that has not been validated through controlled study. It is also worth noting that the exposure profile here is extreme even by heavy-use standards. Drawing conclusions about cannabis users from someone who consumed approximately 3 grams daily of concentrate for six years is like drawing conclusions about alcohol from someone who drank a fifth of grain alcohol every day. The biology may overlap, but the exposure sits at the far tail of the distribution, and generalizing from it to the broader population of older cannabis users would be a significant inferential error.

What would I say to a patient in a similar situation? If you have been using large amounts of high-potency cannabis for years and are considering stopping, please involve your doctor. Abrupt cessation may carry psychiatric risks for certain people, and we can help you approach this more safely with monitoring and, potentially, gradual tapering. To a colleague, I would say this case adds to a small but coherent signal: take a cannabis cessation history when evaluating new-onset psychosis in older adults, and consider gradual rather than abrupt discontinuation in those with heavy use histories and psychiatric vulnerability. To a policymaker, I would say the appropriate response is not alarm but investment in the prospective cohort studies and pharmacovigilance systems that can answer what case reports can only ask. This carefully documented case of a 67-year-old woman who developed paranoid delusions weeks after stopping years of heavy cannabis concentrate use represents exactly what a good case report should be: a clinically coherent observation, honestly framed, contributing to an emerging pattern. What it is not, and should not be presented as, is proof. Temporal proximity is not causation, but it is a legitimate clinical signal worth taking seriously while remaining honest about what we can and cannot infer from a single patient’s experience.

This case report sits at the very beginning of a research arc. It joins a handful of similar observations compiled in the Chesney et al. (2024) systematic review, which identified 44 individuals across 21 reports describing psychosis after cannabis cessation. The entire evidence base remains at the case report and case series level. No prospective cohort, case-control, or randomized study has examined this phenomenon. The clinical pattern described here, where psychotic symptoms emerge weeks after cessation rather than during intoxication, is noteworthy because it could be missed entirely if clinicians do not specifically inquire about recent cannabis discontinuation when evaluating new-onset psychosis in older patients with heavy use histories.

From a pharmacological standpoint, the treatment approach used here, risperidone titrated to 2 mg per day, is pragmatic but carries specific concerns in this population. Risperidone carries an FDA black-box warning regarding increased mortality in elderly patients with dementia-related psychosis. While this patient did not carry a dementia diagnosis, the presence of chronic microvascular white matter disease and advanced age warrants careful risk-benefit deliberation. The successful four-month taper with sustained remission suggests the psychotic episode was self-limited, which is clinically reassuring. For clinicians seeing heavy cannabis users who are planning cessation, the most concrete recommendation from this literature is to consider gradual tapering rather than abrupt discontinuation in those with pre-existing psychiatric vulnerability, combined with close psychiatric monitoring during the first one to two months after cessation.

This is a single-patient case report published in a peer-reviewed journal. Case reports occupy the base of the evidence hierarchy. They are valuable for documenting rare or novel clinical phenomena and generating hypotheses, but they cannot establish causation, measure prevalence, or support generalization. The single most important inference constraint is that no design feature of a case report can control for confounding variables, meaning the many pre-existing psychiatric and psychosocial factors present in this patient cannot be separated from the cannabis cessation itself as potential causes of the psychotic episode.

This case is consistent with and extends the findings of the Chesney et al. (2024) systematic review, which identified a pattern of psychotic symptoms following cannabis cessation across 44 individuals in 21 reports. It also aligns with the Di Forti et al. (2019) multi-center study that established a dose-response relationship between high-potency cannabis use and psychosis risk, though that work focused on psychosis during use rather than after cessation. The current case adds a geriatric dimension that has been largely absent from the literature and introduces the specific context of cannabis concentrates rather than conventional flower. Importantly, the entire supporting evidence base remains observational and at the case report level, meaning this case confirms a recognizable pattern but does not advance the evidence tier.

Formal statistical analysis is not applicable to a single-patient case report. However, the most consequential analytical omission is the absence of structured diagnostic evaluation for bipolar spectrum disorder. Collateral history described lifelong “highs and lows,” and a manic or mixed episode could present with psychotic features indistinguishable from the presentation described. Had a structured diagnostic instrument such as the SCID or MDQ been administered and revealed bipolar pathology, the clinical interpretation would shift substantially from “cannabis withdrawal-associated psychosis” to “bipolar psychotic episode precipitated by the stress of cessation.” Similarly, formal use of validated symptom severity scales such as the BPRS or PANSS would have provided quantifiable outcome data rather than qualitative clinical narrative alone.

The most likely and most consequential misreading is that this case proves cannabis withdrawal causes psychosis. It does not. It documents a temporal association in one patient with multiple confounding vulnerabilities. A related overinterpretation is generalizing this case to all cannabis users who stop using. This patient’s exposure profile, approximately 3 grams per day of concentrate for six years, is at the extreme tail of the distribution, far exceeding what typical users consume. Drawing broad conclusions about cessation risk from this case would be like drawing conclusions about alcohol withdrawal seizures from someone who drank a fifth of grain spirits daily. The biology may be relevant, but the exposure context is not representative. Finally, the fact that symptoms resolved with treatment does not confirm the cause; antipsychotics can resolve psychosis regardless of etiology.

This case report contributes a detailed and honestly framed geriatric observation to a small but coherent body of literature describing psychosis following cannabis cessation. It does not establish that cannabis withdrawal causes psychosis, determine who is at risk, or validate a treatment protocol. For clinical practice today, it supports the straightforward recommendation to take a thorough cannabis history when evaluating new-onset psychosis in older adults and to consider gradual tapering with psychiatric monitoring when helping heavy, long-term users discontinue high-potency products.

Does this case prove that stopping cannabis can cause psychosis?

No. This is a single case report, which is the lowest tier of clinical evidence. It documents a temporal association between cannabis cessation and psychosis in one individual with multiple pre-existing psychiatric conditions and psychosocial stressors. A proven causal relationship would require controlled studies comparing groups of people who do and do not stop cannabis under similar conditions.

Should I be worried about stopping cannabis if I use it regularly?

For most people who use cannabis at typical doses, stopping is not associated with psychosis. This case involved an extremely heavy pattern of use, roughly 3 grams per day of high-potency concentrate for six years, combined with pre-existing mental health conditions. If you use cannabis regularly and want to stop, talking to your doctor about a gradual plan is a reasonable precaution, especially if you have a history of depression, anxiety, or other psychiatric conditions.

Is cannabis withdrawal a recognized medical condition?

Cannabis withdrawal syndrome is recognized in the DSM-5 and typically includes irritability, sleep disturbances, decreased appetite, and anxiety. These symptoms are generally mild and self-limited. What this case describes, psychosis emerging weeks after cessation, is a proposed but not yet validated extension of the withdrawal concept and remains under investigation.

Why did this patient’s psychosis appear four weeks after stopping rather than immediately?

The delayed onset is one of the clinically notable features of this case. THC stored in fat tissue is released slowly over weeks, and some researchers have proposed that delayed neurochemical rebalancing after prolonged heavy use may contribute to a window of psychiatric vulnerability. However, this is a hypothesis rather than an established mechanism, and the delay could also reflect independent psychiatric decompensation that coincidentally followed cessation.

Have thoughts on this? Share it: